Teva Pharm Stock Price, News & Analysis

Teva Pharmaceutical (NYSE: TEVA) published its 2024 Healthy Future Report, highlighting significant sustainability achievements. The company surpassed several key targets ahead of schedule, including a 29% reduction in greenhouse gas emissions (exceeding 25% target) and launching nine access to medicine programs (surpassing target of eight). Teva donated approximately 18 million doses of medicine worth $23 million and provided 2.2 million doses at low cost, reaching 187,000 patients. The company achieved strong compliance metrics with 99% of employees trained on ethics and 41% of significant suppliers evaluated for sustainability. Teva's generic medicines contributed to $39.7 billion in healthcare savings across 22 countries. The company received improved sustainability scores from rating organizations, including its highest score from EcoVadis, demonstrating progress in environmental, social, and governance initiatives.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced its upcoming Innovation & Strategy Day, scheduled for Thursday, May 29, 2025, in New York City. The event will run from 8:30 AM to 12:30 PM Eastern Time. CEO Richard Francis and the executive management team will present updates on the company's strategy, focusing on the acceleration phase, growth initiatives, and innovation priorities.

Due to limited capacity, in-person attendance is invitation-only, with analysts and institutional investors requiring pre-registration. A live webcast will be available on Teva's Investor Relations website, with archived content accessible within 24 hours after the event.

Teva (TEVA) reported strong Q1 2025 results, marking its ninth consecutive quarter of revenue growth. The company achieved revenues of $3.9 billion, a 5% increase in local currency terms. Key innovative medicines showed remarkable growth: AUSTEDO revenues reached $411 million (+39%), AJOVY hit $139 million (+26%), and UZEDY generated $39 million. The generics business grew across all regions. Teva improved its 2025 outlook, projecting revenues of $16.8-17.2 billion and non-GAAP EPS of $2.45-2.65. The company announced targeted programs to deliver ~$700 million in net savings by 2027, aiming to achieve a 30% operating margin. Q1 2025 showed solid performance with GAAP EPS of $0.18 and non-GAAP EPS of $0.52, an 8% year-over-year increase.

The FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with Stelara® (ustekinumab) for Teva Pharmaceuticals (TEVA) and Alvotech (ALVO). The approval, effective April 30, 2025, covers all presentations matching the reference product. SELARSDI is indicated for treating moderate to severe plaque psoriasis, active psoriatic arthritis in patients 6+ years, and moderately to severely active Crohn's disease and ulcerative colitis in adults. The drug is available in multiple presentations: 45 mg/0.5 mL and 90 mg/mL prefilled syringes, 45 mg/0.5 mL single-dose vial, and 130 mg/26 mL IV infusion vial. This marks Teva's second FDA-approved interchangeable biosimilar following SIMLANDI®, with three additional biosimilar candidates under FDA review with BsUFA goal dates in Q4 2025.

Teva Pharmaceuticals and Samsung Bioepis have announced the U.S. availability of EPYSQLI® (eculizumab-aagh), a biosimilar to Soliris®. The treatment is now accessible for patients with rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG) in AchR antibody positive adults.

EPYSQLI will be offered at a 30% discount compared to Soliris's Wholesale Acquisition Cost, making it one of the most cost-effective biosimilars in the U.S. The FDA approved EPYSQLI in July 2024 for PNH and aHUS treatments, with gMG indication added in November 2024.

Under their January 2025 partnership, Samsung Bioepis manages development, manufacturing, and supply, while Teva handles U.S. commercialization. The FDA has provisionally determined EPYSQLI to be interchangeable with Soliris® after exclusivity expiration for the first interchangeable biosimilar.

Teva Pharmaceuticals (NYSE: TEVA) announced the FDA's acceptance of its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab) to expand its use to pediatric episodic migraine prevention in patients aged 6-17 years weighing 45kg or more.

The application is supported by positive Phase 3 SPACE trial results, which showed statistically significant improvements in reducing monthly migraine and headache days versus placebo. If approved, AJOVY would become the first calcitonin gene-related peptide (CGRP) antagonist for both adult migraine prevention and pediatric episodic migraine prevention.

AJOVY, initially approved in the U.S. in 2018 for adult migraine prevention, is currently the only anti-CGRP treatment available in both quarterly and monthly dosing options. The treatment is also approved in Europe, Canada, Australia, and Japan.

Teva Pharmaceuticals has announced promising results from their Phase 3 SOLARIS trial survey for TEV-'749, a once-monthly subcutaneous long-acting injectable treatment for schizophrenia. The survey revealed high satisfaction rates among participants:

• Over 92% of patients were satisfied with the initiation regimen and dosing schedule
• 87% of nurses and 72% of physicians expressed satisfaction with the treatment
• 78.6% of patients preferred subcutaneous over intramuscular injection

The study included 70 patients, 24 nurses, and 11 physicians. Notable findings showed that 90% of patients would prefer an LAI without post-injection monitoring, and 72.9% favored a single-injection initiation regimen. The data was presented at the 2025 SIRS Congress in Chicago, highlighting TEV-'749's potential as a new treatment option for schizophrenia using MedinCell's SteadyTeq™ technology.

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced the release of its Q1 2025 Aide Memoire, now available on the company's investor relations webpage. The document is designed to assist in financial modeling of quarterly results, incorporating previous performance data, management commentary on business outlook, and select third-party source information.

The company has indicated its intention to provide this information regularly towards the end of each quarter going forward.

Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will publish its Q1 2025 financial results press release on Wednesday, May 7, 2025, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET the same day.

Interested participants must register in advance to obtain local or toll-free phone numbers and personal pins. The webcast will be accessible through Teva's investor relations website, with a replay available within 24 hours after the call conclusion.